drugset
drugset / Trial / NCT05087602

Toripalimab Combined With Anlotinib in Unresectable Locally Advanced or Metastatic Acral Malignant Melanoma

NCT05087602 ↗

Phase 2 Unknown 29 enrolled Qilu Hospital of Shandong University
NaSingle-groupOpen-labelTreatment

Summary

Evaluate PFS of PD-1 Toripalimab Combined With Anlotinib in Subjects With unresectable locally advanced or metastatic acral malignant melanoma

Timeline

Start
2021-11-01
Primary completion
2023-09-30
Completion
2023-10-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Catequentinib Small molecule 10 mg Oral
Subject Toripalimab Monoclonal antibody 240 mg Intravenous

Indications

acral lentiginous melanoma